LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

246.06 3.17

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

238.05

Max

246.62

Schlüsselkennzahlen
By Trading Economics
Einkommen	41M 79M
Verkäufe	1.8M 98M
KGV Branchendurchschnitt	35.09 77.671
Gewinnspanne	81.15
Angestellte	275
EBITDA	10M 50M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	-7.5% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.3B 6.8B
Vorheriger Eröffnungskurs	242.89
Vorheriger Schlusskurs	246.06

Nachrichtenstimmung

By Acuity

53%

47%

314 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

133.221 / 169.73 Unterstützung & Widerstand

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Dez. 2025, 23:58 UTC

Akquisitionen, Fusionen, Übernahmen

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11. Dez. 2025, 23:56 UTC

Ergebnisse

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11. Dez. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11. Dez. 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11. Dez. 2025, 21:50 UTC

Ergebnisse

Costco Same-Store Sales, Membership Fees Rose in 1Q

11. Dez. 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

11. Dez. 2025, 23:44 UTC

Market Talk

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11. Dez. 2025, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11. Dez. 2025, 23:31 UTC

Ergebnisse

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. Dez. 2025, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11. Dez. 2025, 22:35 UTC

Ergebnisse

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11. Dez. 2025, 22:30 UTC

Ergebnisse

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11. Dez. 2025, 22:09 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11. Dez. 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11. Dez. 2025, 22:05 UTC

Ergebnisse

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. Dez. 2025, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

11. Dez. 2025, 21:39 UTC

Ergebnisse

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11. Dez. 2025, 21:39 UTC

Ergebnisse

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11. Dez. 2025, 21:38 UTC

Ergebnisse

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11. Dez. 2025, 21:37 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11. Dez. 2025, 21:37 UTC

Market Talk

Broadcom Sees AI Revenue Doubling -- Market Talk

11. Dez. 2025, 21:34 UTC

Akquisitionen, Fusionen, Übernahmen

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11. Dez. 2025, 21:29 UTC

Akquisitionen, Fusionen, Übernahmen

Dexus Aiming for Long-Term Holding of A$50M in Fund

11. Dez. 2025, 21:28 UTC

Market Talk

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

Dexus: Third Party Investors to Contribute Remainder

11. Dez. 2025, 21:27 UTC

Akquisitionen, Fusionen, Übernahmen

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11. Dez. 2025, 21:26 UTC

Akquisitionen, Fusionen, Übernahmen

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11. Dez. 2025, 21:25 UTC

Akquisitionen, Fusionen, Übernahmen

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

-7.5% Nachteil

12-Monats-Prognose

Durchschnitt 221.75 USD -7.5%

Hoch 255 USD

Tief 198 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

133.221 / 169.73Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Stimmung

By Acuity

314 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.